Business
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer’s Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL. The
About this update from Biovie Inc.
[{"type":"image","alt":"BioVie, Inc.","displaySize":"","headline":null,"caption":"BioVie, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/74wuLVBY92R9d2c1AJ.QhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3ea77a11e9aebc3c51a1eb5247357a7a","width":300,"height":79}},"lazy":false},{"type":"text","content":"CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer’s Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL.","length":496,"tagName":"p"},{"type":"text","content":"The two abstracts have been accepted for presentation as posters during a session to be held on February 18, 2026. Details of the abstracts are as follows:","length":155,"tagName":"p"},{"type":"text","content":"Abstract Title: Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer’s Disease","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"Authors: Joseph M. Palumbo1; Christopher L. Reading1; Jiayan Yan1, Clarence Ahlem1; Penelope Markham1; Stephen O’Quinn1; Varun B. Dwaraka2","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"Authors: Joseph M. Palumbo1*; Penelope Markham1; Michael Peluso3; Igor J. Koralnik4; Sherry Hsiang-Yi Chou4; Lisa McCorkell5; Chantal Petit6; Stephen O’Quinn7; Chris Reading1; Clarence Ahlem1; Jiayan Yan1","length":204,"tagName":"p","attribs":{}},{"type":"text","content":"Affilations: 1BioVie Inc., 2TruDiagnostic, Inc., 3University of California, San Francisco; 4Feinberg School of Medicine, Northwestern University; 5Patient-Led Research Collaborative, Oakland, Califor...